- Home
- SUPV vs INBX Comparison
SUPV vs INBX Comparison
Compare SUPV & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | INBX |
|---|---|---|
| Founded | 1887 | 2010 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.9M | 1.1B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUPV | INBX |
|---|---|---|
| Price | $10.57 | $76.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 201.6K |
| Earning Date | 03-09-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $396,684,246.00 | $1,400,000.00 |
| Revenue This Year | $12.75 | $563.00 |
| Revenue Next Year | $45.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.54 | $10.81 |
| 52 Week High | $17.02 | $94.57 |
Technical Indicators
Market Signals| Indicator | SUPV | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 56.01 |
| Support Level | $10.22 | $77.24 |
| Resistance Level | $12.14 | $88.72 |
| Average True Range (ATR) | 0.77 | 4.93 |
| MACD | -0.09 | 0.54 |
| Stochastic Oscillator | 18.67 | 68.86 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.